Compare Peptides
Select any two compounds for a side-by-side comparison of mechanism, uses, risks, and FDA regulatory status.
Popular comparisons
A 21-amino acid peptide encoded within the mitochondrial genome — one of the first mitochondria-derived peptides (MDPs) discovered. Humanin levels decline with age and are associated with longevity in centenarian offspring. Studied for neuroprotection, metabolic health, and cardiovascular protection.
A synthetic tetrapeptide (Ala-Glu-Asp-Gly) originally developed by the St. Petersburg Institute of Bioregulation and Gerontology in Russia. Studied for telomere lengthening, melatonin regulation, and anti-aging properties.
Binds to multiple receptors including gp130, FPRL1, and intracellular IGFBP-3. Activates STAT3 and AMPK signaling pathways. Inhibits neuronal apoptosis, reduces inflammation, improves insulin sensitivity, and protects against ischemic injury. Acts as a stress-response signal from mitochondria to the rest of the cell.
Stimulates the pineal gland to increase melatonin production. Activates telomerase, an enzyme that maintains telomere length, potentially slowing cellular aging. Also reported to normalize circadian rhythms and modulate neuroendocrine function.
- Neuroprotection and cognitive support
- Metabolic health and insulin sensitivity
- Cardiovascular protection
- Longevity and anti-aging protocols
- Alzheimer's disease research
- Anti-aging and longevity protocols
- Improved sleep quality
- Telomere length maintenance
- Cancer prevention (preliminary research)
- Circadian rhythm regulation
- Very limited human clinical data
- Optimal dosing not established
- Long-term effects unknown
- Injection site reactions
- Interactions with other peptides not well characterized
- Very limited human clinical data
- Most research from Russian institutions with limited peer review
- Long-term safety unknown
- Injection site reactions
- Theoretical concerns around telomerase activation and oncogenesis
Not FDA-approved and not on any compounding list. Available as a research chemical. One of the more scientifically interesting longevity peptides with a growing research base, but human clinical trials are in early stages. Not affected by the 2026 regulatory changes.
Removed from FDA 503A Category 2 effective April 22, 2026. Scheduled for PCAC review on July 24, 2026. Most research originates from Russian institutions; limited independent Western replication. Compounding not yet authorized — status is in regulatory gray zone pending PCAC recommendation.
PCAC: July 24, 2026
This comparison is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy.